Clinical aspects of visceral leishmaniasis in HIV infection

Current Opinion in Infectious Diseases

Volumn 26, Issue 1, 2013, Pages 1-9

  Jarvis, Joseph N ^a,b   Lockwood, Diana N ^a,b  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

AIDS; HIV; Leishmania; leishmaniasis; visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; MILTEFOSINE; PENTAMIDINE; STIBOGLUCONATE SODIUM;

AGGLUTINATION TEST; ANTIVIRAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PROPHYLAXIS; REVIEW; SEROLOGY; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEISHMANIASIS, VISCERAL; SEROLOGIC TESTS;

EID: 84871803448     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835c2198     Document Type: Review

References (83)

1. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319. (Pubitemid 27196673)
2. Ngouateu OB, Kollo P, Ravel C, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg 2012; 106:137-142.
3. Guimaraes LH, Machado PR, Lago EL, et al. Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil. Trans R Soc Trop Med Hyg 2009; 103:712-715.
4. Khandelwal K, Bumb RA, Mehta RD, et al. A patient presenting with diffuse cutaneous leishmaniasis (DCL) as a first indicator of HIV infection in India. Am J Trop Med Hyg 2011; 85:64-65.
5. Guerra JA, Coelho LI, Pereira FR, et al. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. Am J Trop Med Hyg 2011; 85:524-527.
6. Andreani G, Lodge R, Richard D, Tremblay MJ. Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS 2011; 7: 276-282.
7. Alexander J, Brombacher F. T helper1/T helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol 2012; 3:80.
8. Morales MA, Cruz I, Rubio JM, et al. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis 2002; 185:1533-1537. (Pubitemid 34507981)
9. Colomba C, Saporito L, Vitale F, et al. Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis 2009; 9:199.
10. Orsini M, Canela JR, Disch J, et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg 2012; 106:283-288.
11. Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011; 53:e152-e158.
12. Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011; 53:e91-e98.
13. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval ME, et al. HIV/AIDSassociated visceral leishmaniasis in patients from an endemic area in Centralwest Brazil. Mem Inst Oswaldo Cruz 2010; 105:692-697.
14. Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 2010; 15:848-855.
15. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334-359. (Pubitemid 351555511)
16. Lodge R, Ouellet M, Barat C, et al. HIV-1 promotes intake of Leishmania parasites by enhancing phosphatidylserine-mediated, CD91/LRP-1-dependent phagocytosis in human macrophages. PLoS One 2012; 7:e32761.
17. Garg R, Barat C, Ouellet M, et al. Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. PLoS Negl Trop Dis 2009; 3:e441.
18. Mock DJ, Hollenbaugh JA, Daddacha W, et al. Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog 2012; 8:e1002635.
19. Santos-Oliveira JR, Giacoia-Gripp CB, Alexandrino de Oliveira P, et al. High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis 2010; 10:358.
20. Santos-Oliveira JR, Regis EG, Leal CR, et al. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis 2011; 5:e1198.
21. Gil-Prieto R, Walter S, Alvar J, deMiguel AG. Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008). Am J Trop Med Hyg 2011; 85:820-825.
22. Campino L, Maia C. [Epidemiology of leishmaniases in Portugal]. Acta Med Port 2010; 23:859-864.
23. WHO. Leishmaniasis: worldwide epidemiological and drug access update. World Health Organization; 2012. http://www.who.int/leishmaniasis/resources/ leishmaniasis-epidemiology-access-to-medicine/en/index.html. [Accessed 21 August 2012]
24. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671. The most up-to-date estimates of global visceral leishmaniasis disease burden. Globally, an estimated 200-400 000 cases are thought to occur every year.
25. WHO. Progress Report: global HIV/AIDS response. World Health Organization; 2011. http://www.who.int/hiv/pub/progress-report2011/en/index. html. [Accessed 21 August 2012]
26. Nascimento ET, Moura ML, Queiroz JW, et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg 2011; 105:298-300.
27. Botelho AC, Natal D. [First epidemiological description of visceral leishmaniasis in Campo Grande, State of Mato Grosso do Sul]. Rev Soc Bras Med Trop 2009; 42:503-508.
28. Diro A, Hailu A, Lynen L. VL-HIV co-infection in East-Africa: current challenges and perspectives. 7th European Congress on Tropical Medicine and International Health; 2011; Barcelona.
29. Amann K, Bogdan C, Harrer T, Rech J. Renal leishmaniasis as unusual cause of nephrotic syndrome in an HIV patient. J Am Soc Nephrol 2012; 23: 586-590.
30. Shankar EM, Vignesh R, Murugavel KG, et al. Common protozoans as an uncommon cause of respiratory ailments in HIV-associated immunodeficiency. FEMS Immunol Med Microbiol 2009; 57:93-103.
31. Lencastre A, Joao A, Lopes MJ. Panniculitis in the setting of visceral leishmaniasis. Acta Med Port 2011; 24:649-652.
32. Santos-Oliveira JR, Da-Cruz AM, Pires LH, et al. Atypical lesions as a sign of cutaneous dissemination of visceral leishmaniasis in a human immunodeficiency virus-positive patient simultaneously infected by two viscerotropic Leishmania species. Am J Trop Med Hyg 2011; 85:55-59.
33. Gelanew T, Hurissa Z, Diro E, et al. Disseminated cutaneous leishmaniasis resembling postkala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia. Am J Trop Med Hyg 2011; 84:906-912.
34. Barragan P, Lopez-Velez R, Olmo M, Podzamczer D. Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2010; 83:10-12.
35. Bourgeois N, Bastien P, Reynes J, et al. 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 2010; 11:670-673.
36. de Souza GF, Biscione F, Greco DB, Rabello A. Slow clinical improvement after treatment initiation in Leishmania/HIV coinfected patients. Rev Soc Bras Med Trop 2012; 45:147-150.
37. de Araujo VE, Morais MH, Reis IA, et al. Early clinical manifestations associated with death from visceral leishmaniasis. PLoS Negl Trop Dis 2012; 6:e1511.
38. Herrero M, Orfanos G, Argaw D, et al. Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg 2009; 81:373-377.
39. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-364. (Pubitemid 44078909)
40. Hailu W, Weldegebreal T, Hurissa Z, et al. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg 2010; 104:706-712.
41. ter Horst R. Management of visceral leishmaniasis-HIV co-infection: experience from the field. Addis Ababa: ICASA; 2011.
42. ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-1709. (Pubitemid 351706767)
43. WHO. Control of the leishmaniasis. Report of a meeting of the WHO Expert Committee on the control of leishmaniases; 22-26 March 2010; Geneva. Geneva: World Health Organization; 2010. Technical report series no. 949.
44. ter Horst R, Tefera T, Assefa G, et al. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 2009; 80:929-934.
45. Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2011; 105:1-6.
46. Ritmeijer K, Melaku Y, Mueller M, et al. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg 2006; 74:76-80. (Pubitemid 46768633)
47. Chappuis F, Mueller Y, Nguimfack A, et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 2005; 43: 5973-5977. (Pubitemid 43100646)
48. Sundar S, Singh RK, Maurya R, et al. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg 2006; 100:533-537.
49. Deniau M, Canavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann Trop Med Parasitol 2003; 97 (Suppl 1):115-133.
50. Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis 2012; 6:e1665.
51. MSF. Focus on kala azar (leishmaniasis). Medecins Sans Frontieres; 2012. http://www.msf.org.uk/kalaazar.focus. [Accessed 21 August 2012]
52. Sundar S, Agrawal S, Pai K, et al. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 2005; 73:269-271. (Pubitemid 41278696)
53. Salam MA, Khan MG, Mondal D. Urine antigen detection by latex agglutination test for diagnosis and assessment of initial cure of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2011; 105:269-272.
54. ter Horst R. MSF: initial outcomes of combination treatment for HIV and visceral leishmaniasis co-infection. PLoS Blogs 3 January 2012. (http://blogs.plos.org/speakingofmedicine/2012/01/03/msf-initial-outcomes- ofcombination-treatment-for-hiv-and-visceral-leishmaniasis-co-infection/. [Accessed 21 August 2012]
55. MSF. The double burden: HIV/visceral leishmaniasis co-infection in East Africa. MSF Briefing Note 2011; December 2011.www.msfaccess.org/content/double- burden-hiv-visceral-leishmaniasis-co-infection-east-africa. [Accessed 21 August 2012]
56. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis 2010; 2:167-176.
57. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-1107. (Pubitemid 32299375)
58. Sundar S, Jha TK, Thakur CP, et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143-146. (Pubitemid 34755644)
59. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-383. (Pubitemid 38200114)
60. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-512.
61. Mueller M, Ritmeijer K, Balasegaram M, et al. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007; 101:19-24. (Pubitemid 44660703)
62. Edwards T, Omollo R, Khalil EA, et al. Single-dose liposomal amphotericin B (AmBisome) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12:66.
63. Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543-550.
64. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-1823. (Pubitemid 28550072)
65. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-1746. (Pubitemid 35375612)
66. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576-2597.
67. Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009; 3:e355.
68. van Griensven J, Balasegaram M, Meheus F, et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010; 10:184-194.
69. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006; 9:26-39. (Pubitemid 43928805)
70. Seifert K, Perez-Victoria FJ, Stettler M, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007; 30:229-235. (Pubitemid 47135625)
71. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50:73-79. (Pubitemid 43042905)
72. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000-1006.
73. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an openlabel, noninferiority, randomised controlled trial. Lancet 2011; 377:477-486.
74. Rybniker J, Goede V, Mertens J, et al. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure: a case report and brief review of the literature. Int J Infect Dis 2010; 14:e522-e525.
75. Collini P, Premchand N, Lockwood D, Greig J. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIVpositive patient with visceral leishmaniasis: a case report and brief review of the literature. Ann Trop Med Parasitol 2009; 103:455-459.
76. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol 2003; 97 (Suppl 1):29-45.
77. Nelson M, Dockrell DH, Edwards S. British HIV Association and British Infection Association Guidelines for the treatment of opportunistic infection in HIV-seropositive individuals. HIV Med 2011; 12(Suppl 2):1-5.
78. Patel TA, Lockwood DN. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. Trop Med Int Health 2009; 14:1064-1070.
79. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 2011; 5:e1153.
80. Auyeung P, French MA, Hollingsworth PN. Immune restoration disease associated with Leishmania donovani infection following antiretroviral therapy for HIV infection. J Microbiol Immunol Infect 2010; 43:74-76.
81. Tadesse A, Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of antiretroviral therapy (ART). Ethiop Med J 2009; 47:77-79.
82. Patel KK, Patel AK, Sarda P, et al. Immune reconstitution visceral leishmaniasis presented as hemophagocytic syndrome in a patient with AIDS from a nonendemic area: a case report. J Int Assoc Phys AIDS Care (Chic) 2009; 8:217-220.
83. van der Spek BW, Hillebrand-Haverkort ME, Stam F, Kager PA. One of the many faces of immune reconstitution inflammatory syndrome. Clin Infect Dis 2009; 48:764-765; 836-838.